Tarek H. Mouhieddine, MD, on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma With Bispecific Antibodies Treatment

Posted: Sunday, December 12, 2021

Tarek H. Mouhieddine, MD, of The Mount Sinai Hospital and The Icahn School of Medicine at Mount Sinai, discusses findings on the optimal treatment sequences for patients with multiple myeloma who relapse after treatment with bispecific antibodies and the research still needed.